Atracurium Hameln 25 mg/2.5 ml is a Product of the Generic Atracurium Besilate

Atracurium Hameln 25 mg/2.5 ml belongs to the generic category of Atracurium Besilate. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of Atracurium Hameln 25 mg/2.5 ml. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Atracurium Besilate and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

Description of Atracurium Hameln 25 mg/2.5 ml

Atracurium Hameln 25 mg/2.5 ml may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of Atracurium Hameln 25 mg/2.5 ml is provided below to help users gain a clear understanding of this medicine.

What Is Atracurium Hameln 25 mg/2.5 ml Indications and Uses?

Atracurium is indicated for endotracheal intubation, facilitate mechanical ventilation in intensive care, muscle relaxant in general anaesthesia.

Pharmacology (Source, Chemical and Physical Composition) Of Atracurium Hameln 25 mg/2.5 ml

Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

Dosage And Administration of Atracurium Hameln 25 mg/2.5 ml

Adult and Child (>1 month): Initially, 300-600 mcg/kg as bolus IV, with subsequent doses of 100-200 mcg/kg by IV every 15-25 min or 5-10 mcg/kg/min by infusion in prolonged procedures. Higher infusion rate may be used in patients undergoing controlled ventilation in intensive care.

Drug Interactions of Atracurium Hameln 25 mg/2.5 ml

Enhanced neuromuscular blocking effect w/ general anaesth (e.g. enflurane, isoflurane, halothane), certain antibiotics (e.g. aminoglycosides, polymyxins), lithium, Mg salts, procainamide, quinidine.

Side Effects of Atracurium Hameln 25 mg/2.5 ml

Skin flush, erythema, pruritus, urticaria, wheezing, increased bronchial secretions, bronchospasm, cyanosis, angioedema, CV effects (e.g. bradycardia); wheals and erythema at inj site. Potentially Fatal: Anaphylaxis.

Use During Pregnancy and Lactation

Pregnancy Category C: Teratogenic Effects. Atracurium besylate has been shown to be potentially teratogenic in rabbits when given in doses up to approximately one-half the human dose. There are no adequate and well-controlled studies in pregnant women. Atracurium should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Precautions And Warnings for Atracurium Hameln 25 mg/2.5 ml

Patient with CV disease, burn injury, asthma; conditions which may antagonise neuromuscular blockade (e.g. resp alkalosis, hypercalcaemia, demyelinating lesions, peripheral neuropathies, denervation, muscle trauma); conditions which may potentiate neuromuscular blockade (e.g. electrolyte abnormalities, neuromuscular diseases, metabolic acidosis, resp acidosis, Eaton-Lambert syndrome, myasthenia gravis). Pregnancy and lactation.

Therapeutic Class

Non depolarizing muscle relaxants

Storage Conditions of It

Store between 2-8° C. Do not freeze.

Atracurium Hameln 25 mg/2.5 ml is a Product of the Generic Atracurium Besilate